In this issue of JAMA Otolaryngology-Head & Neck Surgery, Saraswathula and colleagues1 used the Surveillance, Epidemiology, and End Results Program (SEER)–Medicare outcomes and claims database to compare the value of 3 different radiotherapy (RT) regimens (ie, RT alone, RT plus cisplatin, or RT plus cetuximab) administered to patients older than 65 years with locally advanced head and neck cancer (HNC) of the oral cavity, oropharynx, larynx, and hypopharynx. In this setting, RT plus cetuximab was not associated with improved survival compared with RT alone, but it was associated with an increased number of emergency department visits and increased costs. The authors concluded that cetuximab concurrently administered with RT seems to be of low value in terms of improved survival and higher costs for older patients with HNC.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Galloway TJ, Ridge JA. Treatment of Head and Neck Cancer—Sometimes, Less Is More. JAMA Otolaryngol Head Neck Surg. 2019;145(12):1167–1169. doi:10.1001/jamaoto.2019.3078
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: